Press Releases Year None202320222021202020192018 Nov 13, 2023 Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Nov 10, 2023 Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023 Nov 08, 2023 Akero Therapeutics to Present at Upcoming Healthcare Conferences in November Oct 17, 2023 Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference Oct 10, 2023 Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip Oct 09, 2023 Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Oct 04, 2023 Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology Aug 31, 2023 Akero Therapeutics to Present at Upcoming Healthcare Conferences in September Aug 28, 2023 Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 Aug 11, 2023 Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
Year None202320222021202020192018 Nov 13, 2023 Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Nov 10, 2023 Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023 Nov 08, 2023 Akero Therapeutics to Present at Upcoming Healthcare Conferences in November Oct 17, 2023 Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference Oct 10, 2023 Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip Oct 09, 2023 Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Oct 04, 2023 Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology Aug 31, 2023 Akero Therapeutics to Present at Upcoming Healthcare Conferences in September Aug 28, 2023 Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 Aug 11, 2023 Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
Nov 13, 2023 Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 10, 2023 Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Oct 17, 2023 Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
Oct 10, 2023 Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip
Oct 09, 2023 Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Oct 04, 2023 Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Aug 11, 2023 Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
